PROKIDNEY CORP.(PROK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,652 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PROK Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for PROKIDNEY CORP. (PROK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PROK at 25.8/100 on a 32-signal composite quality model, placing it at rank #2,652 of 2,962 stocks — the bottom half of the AI-ranked universe. PROK scores in the top quartile across revenue growth (98.4), institutional flow (92.2). Areas of concern include free cash flow (0.2) and revenue scale (0.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PROKIDNEY CORP. reports quarterly revenue of $150.0K, net income of $-28.4M, free cash flow of $-44.2M. Top institutional holders of PROK by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, MORGAN STANLEY, BlackRock, based on the most recent SEC filings. PROK trades on the Nasdaq exchange and files with the SEC under CIK 1850270. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PROK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PROKIDNEY CORP. directly from SEC EDGAR. PROKIDNEY CORP.'s 13F Pro composite quality score has ranged between 14 and 28 since 2026, currently 25.8 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$150.0K
Net Income
Q2 2026
$-28.4M
Free Cash Flow
Q2 2026
$-44.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+1075.0% YoYNet Income
-12.7% YoYOperating Income
+10.2% YoYEPS (Diluted)
Total Assets
-23.9% YoYOp. Cash Flow
+4.9% YoYFree Cash Flow
+13.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $893.0K +1075.0% | $76.0K | $0.00 | $0.00 | — | — |
| Net Income | $-69.0M -12.7% | $-61.2M -72.5% | $-35.5M | — | $-55.1M | — |
| Operating Income | $-165.0M +10.2% | $-183.7M -21.2% | $-151.5M +1.0% | $-153.0M -177.6% | $-55.1M -103.9% | $-27.0M |
| EPS (Diluted) | — | — | — | $-0.23 | — | — |
| Total Assets | $335.6M -23.9% | $441.1M +4.9% | $420.6M -18.8% | $518.0M +1185.4% | $40.3M | — |
| Operating Cash Flow | $-120.1M +4.9% | $-126.4M -40.3% | $-90.1M -16.8% | $-77.1M -53.3% | $-50.3M -99.7% | $-25.2M |
| Free Cash Flow | $-135.3M +13.2% | $-155.9M -25.4% | $-124.3M -57.4% | $-78.9M -42.2% | $-55.5M -81.1% | $-30.6M |
Get alerted when PROK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PROKIDNEY CORP. including:
Top Institutional Holders of PROK
SUVRETTA CAPITAL MANAGEMENT, LLC
$25.2M12,341,266 shMORGAN STANLEY
$20.1M9,854,178 shBlackRock, Inc.
$10.6M5,197,227 shGEODE CAPITAL MANAGEMENT, LLC
$4.9M2,390,147 shBleichroeder LP
$4.1M2,000,000 shHennion & Walsh Asset Management, Inc.
$3.8M1,847,749 shArtia Global Partners LP
$3.7M1,806,939 shVANGUARD CAPITAL MANAGEMENT LLC
$2.4M1,175,257 shRENAISSANCE TECHNOLOGIES LLC
$2.2M1,099,400 shMILLENNIUM MANAGEMENT LLC
$2.2M1,054,705 sh
| Fund | Value | Shares |
|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $25.2M | 12,341,266 |
| MORGAN STANLEY | $20.1M | 9,854,178 |
| BlackRock, Inc. | $10.6M | 5,197,227 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.9M | 2,390,147 |
| Bleichroeder LP | $4.1M | 2,000,000 |
| Hennion & Walsh Asset Management, Inc. | $3.8M | 1,847,749 |
| Artia Global Partners LP | $3.7M | 1,806,939 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.4M | 1,175,257 |
| RENAISSANCE TECHNOLOGIES LLC | $2.2M | 1,099,400 |
| MILLENNIUM MANAGEMENT LLC | $2.2M | 1,054,705 |
Companies Similar to PROK
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Atai Beckley N.V.
TScan Therapeutics, Inc.
Altimmune, Inc.
Inhibrx Biosciences, Inc.
Rafael Holdings, Inc.
Upstream Bio, Inc.
Tonix Pharmaceuticals Holding Corp.
LEXICON PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PROK on your watchlist
Track score changes the day PROKIDNEY CORP. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PROK a good stock to buy?
13F Pro's AI-powered analysis of PROKIDNEY CORP. (PROK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PROK are available on the PROK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PROK is classified as a small company.
Which hedge funds own PROK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PROK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PROKIDNEY CORP.'s investment landscape.